These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 27802904)
1. Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells. Wasim L; Chopra M Biomed Pharmacother; 2016 Dec; 84():1393-1405. PubMed ID: 27802904 [TBL] [Abstract][Full Text] [Related]
2. Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells. Wasim L; Chopra M Cell Oncol (Dordr); 2018 Apr; 41(2):201-212. PubMed ID: 29260509 [TBL] [Abstract][Full Text] [Related]
3. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023 [TBL] [Abstract][Full Text] [Related]
4. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells. Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193 [TBL] [Abstract][Full Text] [Related]
5. Suberoylanilide hydroxamic acid-induced HeLa cell death is closely correlated with oxidative stress and thioredoxin 1 levels. You BR; Park WH Int J Oncol; 2014 May; 44(5):1745-55. PubMed ID: 24626405 [TBL] [Abstract][Full Text] [Related]
6. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781 [TBL] [Abstract][Full Text] [Related]
7. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model. Waldeck K; Cullinane C; Ardley K; Shortt J; Martin B; Tothill RW; Li J; Johnstone RW; McArthur GA; Hicks RJ; Wood PJ Int J Cancer; 2016 Jul; 139(1):194-204. PubMed ID: 26914605 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203 [TBL] [Abstract][Full Text] [Related]
9. Glycyrrhizin induces reactive oxygen species-dependent apoptosis and cell cycle arrest at G Farooqui A; Khan F; Khan I; Ansari IA Biomed Pharmacother; 2018 Jan; 97():752-764. PubMed ID: 29107932 [TBL] [Abstract][Full Text] [Related]
11. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Pei XY; Dai Y; Grant S Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093 [TBL] [Abstract][Full Text] [Related]
12. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. Lachenmayer A; Toffanin S; Cabellos L; Alsinet C; Hoshida Y; Villanueva A; Minguez B; Tsai HW; Ward SC; Thung S; Friedman SL; Llovet JM J Hepatol; 2012 Jun; 56(6):1343-50. PubMed ID: 22322234 [TBL] [Abstract][Full Text] [Related]
13. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Thomas S; Aggarwal R; Jahan T; Ryan C; Troung T; Cripps AM; Raha P; Thurn KT; Chen S; Grabowsky JA; Park J; Hwang J; Daud A; Munster PN Ann Oncol; 2016 May; 27(5):947-52. PubMed ID: 26903311 [TBL] [Abstract][Full Text] [Related]
14. Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS. Yoshioka T; Yogosawa S; Yamada T; Kitawaki J; Sakai T Gynecol Oncol; 2013 May; 129(2):425-32. PubMed ID: 23403163 [TBL] [Abstract][Full Text] [Related]
15. 18beta-Glycyrrhetinic acid induces apoptotic cell death in SiHa cells and exhibits a synergistic effect against antibiotic anti-cancer drug toxicity. Lee CS; Kim YJ; Lee MS; Han ES; Lee SJ Life Sci; 2008 Sep; 83(13-14):481-9. PubMed ID: 18721818 [TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. Denlinger CE; Rundall BK; Jones DR J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602 [TBL] [Abstract][Full Text] [Related]
17. Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro. Lo YL; Wang W Chem Biol Interact; 2013 Oct; 205(3):188-97. PubMed ID: 23867903 [TBL] [Abstract][Full Text] [Related]
18. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines. Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549 [TBL] [Abstract][Full Text] [Related]
19. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators. Beider K; Bitner H; Voevoda-Dimenshtein V; Rosenberg E; Sirovsky Y; Magen H; Canaani J; Ostrovsky O; Shilo N; Shimoni A; Abraham M; Weiss L; Milyavsky M; Peled A; Nagler A Biochem Pharmacol; 2019 Oct; 168():412-428. PubMed ID: 31325448 [TBL] [Abstract][Full Text] [Related]
20. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]